Samsung Biologics recently made waves by participating in the prestigious 2025 BioProcess International (BPI), a globally recognized bio-industry conference. The event serves as a melting pot for the latest technologies in biopharmaceutical development, production, and analysis, fostering collaborations and discussions among industry experts worldwide.
Taehee Lee, the Executive Director of the Antibody Culture PD Team at Samsung Biologics, took the stage on the 16th to present the company’s innovative approaches. With a history of eight consecutive participations since 2018, Samsung Biologics once again set up a booth to showcase its comprehensive support services spanning the biopharmaceutical lifecycle, from contract research to manufacturing.
During the speaking session, Lee highlighted the company’s Contract Development Organization (CDO) competitiveness, focusing on strategies to expedite clients’ new drug development timelines. By emphasizing early-stage feasibility assessments, risk-based CMC plans, and parallel workflows, Samsung Biologics aims to streamline processes without compromising quality, ultimately shortening the path from candidate selection to IND submission.
Heo Gyeyeon, Head of the CMC Support Team, delved into the realm of analytical methods with a poster presentation on “Joint Analytical Method Qualification.” This innovative approach streamlines the assessment process by integrating method development and evaluation within departments, eliminating the need for technology transfers and enhancing development timelines while ensuring analytical method completeness.
Last year, Samsung Biologics unveiled its new CDO slogan, “Agile. Flexible. Focused on You,” underscoring its commitment to tailored client services. The company continues to bolster its technological prowess to stay ahead in the dynamic biopharmaceutical landscape, promising a client-centric approach and cutting-edge solutions.
As Samsung Biologics shines on the global stage, it remains dedicated to innovation and excellence, positioning itself as a key player in the biopharmaceutical arena. Through its participation in events like BPI, the company cements its reputation as a leader in CDMO services and a pioneer in advancing bioprocessing technologies.
Takeaways:
– Samsung Biologics showcases its CDMO competitiveness at the 2025 BioProcess International, highlighting innovative strategies to accelerate new drug development timelines.
– The company’s focus on early-stage feasibility assessments, risk-based CMC plans, and parallel workflows aims to streamline processes without compromising quality.
– Through initiatives like “Joint Analytical Method Qualification,” Samsung Biologics enhances technology transfer efficiency and accelerates development timelines, ensuring comprehensive analytical methods.
– With a client-centric approach and a commitment to technological advancement, Samsung Biologics solidifies its position as a global leader in biopharmaceutical manufacturing and CDMO services.
Tags: antibody-drug conjugates, bioprocess, analytical methods, sports
Read more on asiae.co.kr